HK Stock Market Move | METIS TECHBIO-P(07666) rises more than 10%, AI pharmaceutical industry enters the period of value validation, the company independently develops AI nano delivery platform.

METIS TECHBIO-P(07666) surged more than 10%, as of the time of publication, it rose by 10.42% to 14.41 Hong Kong dollars, with a turnover of 1433.37 million Hong Kong dollars. In terms of news, since the beginning of this year, the global AI biopharmaceutical sector has seen intensive cooperation, including NVIDIA's joint plan with Eli Lilly to invest up to $1 billion over five years to build an AI drug development laboratory; Google's DeepMind subsidiary Isomorphic Labs completed a $2.1 billion B-round financing; INSILICO and South Korea's SK Biopharmaceuticals reached cooperation in the field of neuroimmunological diseases driven by AI. Shanghai Securities believes that leading domestic AI pharmaceutical companies are making breakthroughs in innovation, continuing to strengthen their presence in the discovery and development of innovative drug candidates, material research, and other areas, enhancing diversified layouts, and accelerating the transformation from concept verification to clinical value realization and industrialization. It is recommended to pay attention to Metis Techbio and others. The core competitiveness of Metis Techbio lies in its independently developed global first AI nanodelivery platform NanoForge. With NanoForge, the company has built more than 10 pipeline products. Among them, three leading clinical assets, namely MTS-004, MTS-201, and MTS-105, target disease areas with significant unmet clinical needs and strong commercial prospects. Metis Techbio has China's first AI-enabled new drug MTS-004 that has completed Phase III clinical trials. MTS-004 is China's first and only drug for PBA (pseudo-bulbar affect) to complete clinical trials, potentially filling the gap in the treatment of PBA in China.